Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.Read more

Precision Medicine: Treating the Sub-groups of Parkinson's

The hunt for disease modifying treatments for Parkinson’s is gathering momentum and important shifts are taking place in the minds of clinicians, researchers and patients. One potentially important development in this area refers to precision medicine: targeting therapies to distinct subgroups of patients based on the specific symptoms or molecular features of their disease.Read more

The Tom Isaacs Award 2018

Nominations are invited for this annual award co-created by the Van Andel Research Institute and The Cure Parkinson's Trust in memory of Tom Isaacs.Read more

How Artificial Intelligence Could Help Repurpose Drugs for Parkinson's

A collaboration between The Cure Parkinson's Trust and Parkinson's UK to identify new treatments for Parkinson's has been awarded the inaugural BenevolentAI Award. This project will use BenevolentAI platform’s vast knowledge graph to analyse and propose new therapy targets for Parkinson’s.Read more

How Human Embryonic Stem Cells Sparked a Revolution

After 20 years of hope, promise and controversy, human embryonic stem cells are reshaping biological concepts and starting to move into the clinic, and dopamine cells made from human embryonic stem cells are paving the way for a new treatment for Parkinson's...Read more

The Cure Parkinson's Trust Chairs CNS Summit, Boston

The recent CNS Summit targeting neurodegenerative diseases was chaired by CPT's Dr Richard Wyse and brought a number of outstanding experts in their field together in this two day symposium...Read more

What is the Link between Diabetes and Parkinson's

Parkinson’s disease (PD) is a complex condition with a variety of causes we don't yet fully understand, and while a small number of cases are associated with genetic mutations, the majority originate from a combination of factors. Understanding the underlying causes of PD is becoming an invaluable route in the discovery of new and promising treatments...Read more

Trial of Repurposed Drug Nilotinib in Parkinson's is Recruiting

This study is an example of the potential of repurposing drugs, already approved to treat other conditions, in Parkinson's. This can lead to faster approved therapies, since repurposed drugs have already been tested for safety and tolerability in Phase 1 trials in humans.Read more

Herantis Pharma begins Recruitment for CDNF Trial

Recruitment has begun for the novel drug candidate CDNF for treatment of neurodegenerative diseases such as Parkinson's. It is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties and is patented internationally by Herantis.Read more

Four New People join The Cure Parkinson's Trust

The Cure Parkinson's Trust is delighted to welcome four new members to the team...Read more

Adaptive Clinical Trials

The purpose of an adaptive design is to make trials more flexible, efficient and fast for those in need of new treatments for conditions with no cure. In an adaptive clinical trial, researchers can add in new drugs or combinations of therapies in response to a patient's improved or deteriorating condition.This area of trial design is of particular interest to CPT.Read more

An Interview with Professor Patrik Brundin

Ben Stecher interviews Professor Patrik Brundin - lead at the Center for Neurodegenerative Science at Van Andel Research Institute and co-editor of the Journal of Parkinson's Disease.Read more

David 'Kid' Jensen Talks about Giving Hope and Helping Others with Parkinson's

Broadcasting legend David 'Kid' Jensen has been living with Parkinson's for five years. He has now chosen to speak out about his diagnosis and his thoughts of the future...Read more

Identifying Treatments for Parkinson’s Using Patient-derived Induced Neurons

The Trustees of CPT have approved funding for this exciting new technique which uses a person with Parkinson's own skin cells to grow neurons affected by their particular type of this disease to then treat with certain drugs.Read more

The Parkinson's 'Pandemic'

With an aging and increasing population, the number of people diagnosed with Parkinson's is increasing exponentially. The recent report by Dr Ray Dorsey and Professor Bastian Bloem reinforces the newly published figures from Parkinson's UK...Read more

Diabetes drug (Bydureon) Showed Potential as Disease-modifying Therapy for Parkinson's: More Research Needed

At a recent meeting, hosted by The Cure Parkinson's Trust, attendees discussed the impact of the recently published Bydureon trial, related research and the next steps needed for GLP-1 agonists in Parkinson's.Read more

AMRC Drug Repurposing Report Published

The Cure Parkinson's Trust's Dr Joy Duffen is very pleased to be involved in the generation of the recent AMRC drug repurposing report and continues to keep in touch with its progress and how best to support drugs for repurposing in the future...Read more

Small Molecule Drug Offers Neuroprotection with Promise for PD

An international team of researchers has shown that a new small-molecule drug can restore brain function and memory in pre-clinical models of Alzheimer's disease. The drug works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envisage that this drug could also be used to treat Parkinson's.Read more

Synpromics collaboration with UCL in gene therapy for Parkinson’s

Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system to develop a gene therapy for Parkinson’s.Read more


Please get behind CPT and commit to help raise funds this #GivingTuesday...Read more